Skip to main content
. 2020 Oct 24;3(1):otaa089. doi: 10.1093/crocol/otaa089

Figure 2.

Figure 2.

Pain relief response with olorinab. Proportion of patients who had ≥30% reduction from baseline in weekly peak AAPS (A), trough AAPS (B), evening trough AAPS (C), and daily AAPS (averaged over peak, trough, and evening trough diary entries; D) with olorinab 25 or 100 mg TID and in all subjects at weeks 4 and 8, and were considered pain relief responders. Pain relief response was assessed using observed data (ie, in subjects with evaluable data at weeks 4 and 8).